Krause und Pachernegg
Verlag für Medizin und Wirtschaft
Artikel   Bilder   Volltext

Mobile Version
A-  |   A  |   A+
Werbung
 
Dia-Präsentation von Merck Gesellschaft mbH.
Micardis(R) - Micardis Plus(R) - Pharmakologie (14 Abbildungen)
Übersicht


Zum ersten Bild Abb. 7: Telmisartan - PPAR-Gamma Abb. 8: SBD - DBD Abb. 9: Normaldosierung Aktuelles Bild - Abb. 10: Dosierung - Alter - Geschlecht Abb. 11: Telmisartan - Harnausscheidung Abb. 12: Dosierung - Nephropathien Abb. 13: Telmisartan - Wechselwirkung Zum letzten Bild
Abbildung 10: Dosierung - Alter - Geschlecht
The pharmacokinetics of telmisartan in the elderly (≥65 years) is similar to that in younger patients, with no accumulation.1 This indicates that changes in hepatic function with increasing age do not affect the clearance of telmisartan. Although plasma concentrations of telmisartan are higher in women, this does not affect the antihypertensive effect nor does it increase the risk for adverse events.1,2 1. Stangier J, et al. Pharmacokinetics of orally and intravenously administered telmisartan in healthy young and elderly volunteers and in hypertensive patients. J Int Med Res 2000; 28: 149–167. 2. Smith DHG, et al. Dose response and safety of telmisartan in patients with mild to moderate hypertension. J Clin Pharmacol 2000; 40: 1380–1390.
 
Dosierung - Alter - Geschlecht
Vorheriges Bild Nächstes Bild   


Abbildung 10: Dosierung - Alter - Geschlecht
The pharmacokinetics of telmisartan in the elderly (≥65 years) is similar to that in younger patients, with no accumulation.1 This indicates that changes in hepatic function with increasing age do not affect the clearance of telmisartan. Although plasma concentrations of telmisartan are higher in women, this does not affect the antihypertensive effect nor does it increase the risk for adverse events.1,2 1. Stangier J, et al. Pharmacokinetics of orally and intravenously administered telmisartan in healthy young and elderly volunteers and in hypertensive patients. J Int Med Res 2000; 28: 149–167. 2. Smith DHG, et al. Dose response and safety of telmisartan in patients with mild to moderate hypertension. J Clin Pharmacol 2000; 40: 1380–1390.
 
copyright © 2003–2017 Krause & Pachernegg GmbH | Sitemap | Impressum
 
Werbung